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1. Introduction 
1,4-Benzodiazepin-2-ones are privileged structures possessing 
an outstanding range of  important medicinal and pharmaceutical 
properties1 including uses as gastrin/cholecystokinin-B 
antagonists,2 anticonvulsant,3 anxiolytic agent,4 anti-HIV,5 and 
HIV-Tat antagonist,6 oxytocin antagonist,7 anti-ischemic agents,8 
neuroprotective effect,9 and antitrypanosomal activity.10 In 
addition, the treatment of neurologic disorders such as Down’s 
syndrome and Alzheimer’s disease has been successfully 
completed by employing these heterocyclic families.11 Several 
palladacycle complexes derived from 1,4-benzodiazepin-2-ones 
and pyrrolo[2,1-c][1,4]benzodiazepinones were found to be 
potent antitumor agents,1b,12 whilst another benzodiazepine 
surrogates were used as antileishmanial agents.13 But 1,4-
benzodiazepin-2-ones and its analogues are predominantly active 
in the central nervous system. For example, it has been reported 
potent nonpeptidal receptor antagonist of the peptide hormone 
cholecystokinin,14 the selective cholecistokinine-A (CCKA) 
antagonist MK-329 1,15  and the selective cholecistokinine-B 
(CCKB) antagonists L-365,260 2,16 and YM022 317 and a 
selective translocator protein (TSPO) agonist Ro5-4864 4 (Figure 
1).8,9,18 
Recently, there have been reported many synthetic strategies to 
investigate novel and/or structurally diverse privileged scaffold 
containing 1,4-benzodiazepin-2-one frameworks. The most 
employed strategy consist in the synthesis of the fully 
functionalized heterocycle.19  
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 Structurally diverse novel 1,4-benzodiazepine analogues 
related to selective CCKA antagonist MK-329, and CCKB 
antagonists L-365,260 and YM022 are prepared via 
palladium-catalyzed three component domino reactions 
involving allenylation-carbonylation-anion capture in one-
pot cascade protocol in good to excellent yields. 
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Figure 1. Several biologically important 1,4-benzodiazepin-2-
ones. 
 
Alternatively, benzodiazepine-2-ones can be used as the 
pharmacophore whose substituents are ready to be introduced or 
modified by conventional synthetic procedures. In this sense, we 
have reported that an amino group bonded to the 3-position of 
benzodiazepine ring reacted with aldehyde to generate the 
corresponding imine, which was the precursor of the azomethine 
ylide via thermal or by metal-catalyzed processes. In this 
contribution, 1,3-dipolar cycloaddition cascade reactions 
occurred with chiral and achiral dipolarophiles affording spiro-
cycloadducts in good to excellent yields.20 
In addition, Grigg’s group experience concerning 
multicomponent21 palladium cascades (A→B→C) have been 
widely demonstrated,22 especially, in those involving oxidative 
addition-intermolecular allene insertion (Scheme 1, eq. a) or 
carbon monoxide insertion (Scheme 1, eq. b) followed by 
nucleophilic addition as terminating reactions.22a,c,h,e,23,24  
 
 
Scheme 1. Domino reactions involved in this contribution. 
 
In this work, novel 1,4-benzodiazepine-2-one analogues are 
synthesized from benzodiazepine-2-one precursors via 
palladium(0)-catalyzed multicomponent reactions based on 
oxidative addition onto species A, followed by allene B insertion 
and final capture with nucleophile C, as well as oxidative 
addition onto species A followed by carbon monoxide B 
insertion and final capture with nucleophile C. In all cases, and 
according to Scheme 1, the terminating step is performed through 
the amino/amido group anchored to the benzodiazepine-2-one 
nucleus.  
 
2. Results and Discussion 
Palladium(0)-catalyzed allenylation-anion capture cascade 
reactions: The three-component reaction involving free amine 1-
methyl-3-amino-1,3-dihidro-5-phenyl-(2H)-1,4-benzodiazepine-
2-one 5,22,23  aryl halides 6 and allene 7a was performed in the 
presence of a catalytic system comprised by Pd2(dba)3 (10 mol%) 
and PPh3 (20 mol%). The final conditions were selected 
according to previous optimizations done in previous works,22b,c 
that means, DMF at 70 ºC for 24-36 h and K2CO3 as base (2 
equiv). Compounds 8a-d were obtained in 84-90% yield 
(Scheme 2). Using this methodology, the incorporation of new 
biologically interesting substituents, as 5-uracyl25 or 2-thienyl,26 
was available increasing the potential activity of products 8a-d. 
 
 
Scheme 2. Palladium(0)-catalyzed allenylation-anion capture 
cascade reactions involving amine 5. 
 
A second version of this cascade palladium-catalyzed 
allenylation-anion capture was successfully attempted with 
benzodiazepinone 9a as nucleophilic terminating agent.27 Using 
identical reaction conditions than those described before, 
substituted and unsubstituted allenes 7 were allowed to react with 
aryl halides 6 and heterocycle 9a, in the presence of Pd2(dba)3 
(10 mol%) and PPh3 (20 mol%) in  DMF at 80 ºC for 48 h. 
Functionalized compounds 10a-d were obtained in 65-92% yield 
in one pot cascade reaction (Scheme 3). X-Ray diffraction 
analysis of structure 10a28 also confirmed the skeleton drawn in 
Scheme 3. 
 
 
10a 
Scheme 3. Palladium(0)-catalyzed allenylation-anion capture 
cascade reactions involving benzodiazepine 9 and X-ray 
diffraction structure of compound 10a. 
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Palladium-catalyzed carbonylation-anion capture cascade 
reactions: A third series of benzodiazepine-2-one analogues were 
prepared from 5 or 9 but employing carbon monoxide instead of 
allenes as relay species in the cascade processes. These reactions 
were accomplished with potassium carbonate (1.2 equiv) and a 
catalytic system comprised by palladium(II) acetate (10 mol%), 
and triphenylphosphine (20 mol%) in toluene at 110 ºC for 26 h. 
First, amine 5 was employed as terminating agent in the 
palladium(0)-catalyzed oxidative addition-carbonylation 
obtaining products 11a and 11b in 89% and 81% yields, 
respectively (Scheme 3, eq. a). Similarly, benzodiazepine-2-ones 
9a (X = H) and 9b (X = Cl)29 were submitted to palladium 
catalyzed carbonylation anion capture reaction affording products 
12a and 12b in 73% and 89% yields, respectively (Scheme 3, eq. 
b). Despite of being a trivial transformation introducing a 
benzoyl group, this procedure permit the use of more complex 
iodoarenes, which are much more accessible than the 
corresponding benzoyl chlorides. In this series a variety of 
reactions conditions were evaluated, such as different catalyst 
systems, but yields were not improved. 
 
Scheme 4. Palladium-catalyzed carbonylation-anion capture 
cascade reactions employing molecules 5 and 9 as starters. 
 
An example of double relay system in a palladium-catalyzed 
cyclization-carbonylation-anion capture reaction was studied. 
Thus the aryl iodide 1330 smoothly reacted with palladium(II) 
acetate (10 mol%) and triphenylphosphine (20 mol%), of 
potassium carbonate (1.2 equiv) in toluene at 100 oC for 26 h 
furnishing product 14 in 78% yield as a 1:1 mixture of 
diastereoisomers (Scheme 5). A similar ratio was observed in the 
earlier stages of the reaction, even at low temperatures. The 
reaction proceeds via 5-exo-trig cyclisation as starting process of 
the palladium cascade reaction.31 Both isomers were separated by 
column chromatography (flash silica) and one of them (anti-14) 
completely characterized after analysis of X-ray diffraction of a 
monocrystal structure32 (Scheme 5). 
 
 
 
 
Scheme 5. Palladium-catalyzed cyclization-carbonylation-anion 
capture from compounds 5 and 13 and X-ray diffraction structure 
of diastereoisomer anti-14. 
 
3. Conclusion 
In conclusion, a variety of 1,4-benzodiazepine-2-one 
derivatives can be accessed through a simple one-pot molecularly 
diverse multicomponent cascade protocol proceeding via 
palladium(0)- catalyzed allenylation anion capture and cascade 
palladium-catalyzed carbonylation anion capture reactions. In 
these processes C(sp2)-C(sp2) + C(sp3)-N(sp3) new bonds and  
C(sp2)-C(sp2) + C(sp2)-N(sp3) new bonds are generated, 
respectively. In addition, with a double relay system, C(sp2)-
C(sp3) + C(sp3)-C(sp2) + C(sp2)-N(sp3) new bonds are easily 
formed using the appropriate starter. With this methodology a 
range of allenes and aryl halides can be employed in good to 
excellent yields tolerating many functional groups. The 
molecular complexity of each component can be increased in 
order to build sophisticated architectures or even natural core 
products.  
 
4. Experimental Section 
4.1. General information 
Melting points were determined on a Kofler hot stage apparatus 
and are uncorrected. Mass spectra were recorded at 70 eV on a 
VG Autospec mass spectrometer. Nuclear magnetic resonance 
spectra and decoupling experiments were determined at 250 MHz 
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on a Q.E 300 instrument and at 500 MHz on a Bruker AM500 
spectrometer as specified. Chemical shifts are given in parts per 
million (δ) downfield from tetramethylsilane as internal standard. 
Spectra were determined in CDCl3 except where otherwise 
stated. The structurally most important peaks of the IR spectra 
(recorded using a Nicolet 510 P-FT-ATR) are listed and 
wavenumbers are given in cm-1. Flash column chromatography 
was performed using silica gel 60 (230-400 mesh). Kieselgel 
columns were packed with silica gel GF254 (Merck 7730). 
Petroleum ether refers the fraction with bp 40-60 ºC unless 
otherwise specified.  Microanalyses were obtained using a Carlo-
Erba Model 1106 instrument. Arylhalides were purchased from 
Aldrich and used as received. In the case of aryliodide 13 was 
prepared according to literature procedure.30 
 
4.2. Synthetic procedures and characterization data 
4.2.1. General procedure for allenylation-anion capture reaction. 
Synthesis of compounds 8 
In a Shlenk tube a solution of aryl halide (1.2 mmol), 
Pd2(dba)3 (92 mg, 0.1 mmol),  PPh3 (52 mg, 0.2 mmol) and 
K2CO3 (276 mg, 2 mmol) in dry DMF (10 mL) was prepared. 
Then free amine 5 (318, 1.2 mmol) was added and the mixture 
was degassed once by the freeze thaw pump.  Allene was 
introduced (1 atm) and the solution stirred at 70 ºC for 24-36 h. 
The Schlenk was cooled to ambient temperature and internal 
pressure was released slowly before filtering the crude mixture 
through a filter paper. The solvent was evaporated under reduced 
pressure to give a solid which was purified by column 
chromatography (flash silica) obtaining compounds 8. 
4.2.1.1. 3-[2-Phenyl-2-propenyl)amino]-1-methyl-5-phenyl-
1,3-dihydro-2H-1,4-benzodiazepin-2-one (8a). Yield: 402 mg 
(88%). Colourless prisms; mp 98-100 ºC (petroleum 
ether/EtOAc). IR (neat): 1792, 1698, 1650 cm-1. δΗ (500 MHz): 
7.86 (m, 1H, ArH), 7.70 (m, 2H, ArH), 7.40-7.60 (m, 5H, ArH),  
7.35 (m, 3H, ArH), 7.14-7.43 (m, 4H, ArH), 6.83 (m, 2H, ArH), 
5.08, 5.53 (2 br. s, CH2=C), 5.37 (s, 1H, NCHN), 3.22, 3.41 (2d,  
J 12.5 Hz, 2H, CH2N), 3.42 (s, 3H, NMe), 3.32 (br. s, 1H, NH). 
δC (126 MHz): 35.8 (Me), 53.9 (CH2N), 83.6 (NCHN), 113.4 
(CH2=C), 115.8, 126.4, 126.5, 127.2, 127.9, 128.6, 129.0, 129.2, 
130.9, 131.0, 131.2, 131.9, 139.6, 146.4 (C=CH2 and ArC), 166.7 
(C=N), 168.6 (C=O). m/z (%) (EI): 381 (M+, 2), 319 (20), 229 
(100) Anal. calcd. for C25H23N3O2: C, 78.70; H, 6.00; N, 11.00, 
found C, 78.85; H, 6.30; N, 11.10. 
 
4.2.1.2. 3-{[2-(4-Acetylphenyl)-2-propenyl]amino}-1-methyl-
5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one (8b). Yield: 
355 mg (84%). Colourless prisms; mp 77-78 ºC (petroleum 
ether/EtOAc). IR (neat): 1790, 1698, 1650, 1604, 1446, 1340 cm-
1
. δΗ (500 MHz): 7.89 (d, 2H, J 7.7Hz, ArH), 7.64-7.58 (m, 5H, 
ArH), 7.40 (m, 1H, ArH), 7.39-7.34 (m, 2H, ArH), 7.32-7.36 (m, 
2H, ArH), 7.21 (m, 1H, ArH), 5.53 (s, 1H, 
C=CH2α), 5.51 (s, 1Η, C=CH2β), 4.40 (s, 1H, CHNH), 4.0 (d, 
1H, J 13.6 Hz, NHCH2α), 3.9 (d, 1H, J 13.6 Hz, NHCH2β), 3.44 
(s, 3H, NMe), 3.05 (br. s, 1H, NH), 2.57 (s, 3H, Me). δC (126 
MHz): 26.6 (28-C), 35.1 (4-C), 48.6 (20-C), 74.7 (1-C), 115.9 
(23-C), 121.5 (6-C), 124.1 (24-C), 126.4 (16-C, 14-C), 128.1 (22-
C, 17-C), 128.3 (13-C), 128.5 (10-C, 15-C), 129.1 (8-C), 129.7 
(7-C), 130.2 (9-C), 131.7 (25-C), 131.7 (29-C), 136.2 (12-C), 
138.4 (5-C), 143.2 (26-C), 144.8 (21-C), 144.9 (30-C), 166.6 (11-
C=N), 168.8 (2-C=O), 197.7 (27-C=O). m/z (%) (EI): 423 (M+, 
10), 389 (6), 260 (17), 237 (100), 221 (85), 201 (62), 174 (19), 
115 (26). HRMS (ES): C27H25N3O2Na requires: 446.1844, found: 
446.1864. Anal. calcd. for C27H25N3O2·0.25H2O (%): C, 75.75; 
H, 5.95; N, 9.80, found C, 75.45; H, 5.95; N, 9.30. 
4.2.1.3. 1-Methyl-5-phenyl-1,3-{[2-(2-thienyl)-2-propenyl] 
amino}-1,3-dihydro-2H-1,4-benzodiazepin-2-one (8c). Yield: 348 
mg (90%). Colourless prisms; mp 133-135 ºC (petroleum 
ether/EtOAc). IR (neat): 1793, 1690, 1604, 1446, 1340 cm-1. 
δΗ (500 MHz): 7.65-7.60 (m, 2H, ArH), 7.55 (m, 1H, ArH), 7.44 
(m, 1H, ArH),7.41- 7.21 (m, 4H, ArH), 7.20- 7.15 (m, 2H, ArH), 
7.13(m, 1H, ArH), 6.95 (m, 1H, ArH), 5.46 (br. s, 1H, C=CH2α), 
5.28 (br. s, 1H, C=CH2β), 4.41 (s, 1H, CHNH), 3.97 (d, 1H, J 
13.7 Hz, NHCH2α), 3.85 (d, 1H, J 13.8 Hz, NHCH2β), 3.44 (s, 
3H, NMe), 2.95 (br. s, 1H, NH). δC (126 MHz): 35.1 (4-C), 48.8 
(20-C), 74.6 (1-C), 112.0 (22-C), 121.4 (24-C), 123.7 (6-C), 
124.0 (26-C), 124.2 (8-C), 127.3 (9-C), 128.3 (14-C, 16-C), 
129.1(10-C), 129.7 (13-C, 17-C), 130.2 (15-C), 130.5 (7-C), 
131.6 (25-C), 138.5 (12-C), 139.5 (5-C), 143.2 (21-C), 143.9 (23-
C), 166.5 (C=O), 169.0 (C=N). m/z (%) (EI): 387 (M+, 10), 371 
(5), 238 (17), 221 (91), 194 (25), 165 (100), 138 (21), 97 (50), 77 
(29) and 51 (9). Anal. calcd. for C23H21N3OS (%): C, 71.10; H, 
5.60; N, 10.90; S, 8.30; found: C, 71.30; H, 5. 50; N, 10.90; S, 
8.30.   
4.2.1.4. 1,3-Dimethyl-5-(1-{[1-methyl-2-oxo-5-phenyl-2,3-
dihydro-1H-1,4-benzodiazepin-3-yl) amino] methyl}vinyl)-2,4 
(1H, 3H)-pyrimidinedione (8d). Yield: 381 mg (86%). Colourless 
prisms; mp 101-103 ºC (petroleum ether/EtOAc). IR (neat): 
3100, 2900, 1698, 1650, 1604, 1446, 1345 cm-1. δΗ (500 MHz): 
7.70 (s, 1H, C=CH), 7.65-7.21 (m, 9H, ArH), 5.68 (br. s, 1H, 
C=CH2α), 5.45 (br. s, 1H, C=CH2β), 4.47 (s, 1H, 
CHNH), 3.95 (d, 1H, J 13.0 Hz, NHCH2α), 3.84 (d, J 12.9 Hz,  
NHCH2β), 3.47 (br. s, 1H, NH), 3.44 (s, 3H, NMe), 3.41 (s, 3H, 
NMe), 3.32 (s, 3H, NMe). δC (126 MHz): 28.0 (NMe), 35.1 
(NMe), 37.1 (NMe), 49.2 (20-C, CH2NH), 74.4 (1-C, CHNH), 
112.9 (22-C), 118.9 (23-C), 121.5 (6-C), 124.5 (24-C), 128.2 (14-
C, 16-C), 128.5 (10-C), 128.9 (13-C, 17-C), 129.6 (9-C), 130.3 
(8-C), 130.6 (7-C), 131.8 (15-C), 138.2 (12-C), 141.3 (5-C), 
142.9 (21-C), 151.3 (27-C=O), 162.5 (30-C=O), 166.9 (2-C=O), 
168.4 (11-C=N). m/z (%) (EI): 443 (M+, 7), 409 (9), 260 (11), 
237 (33), 221 (100), 194 (37), 165 (15), 109 (8), 77 (14) and 42 
(31). HRMS (ES): C25H25N5O3Na requires 444.2050; found: 
444.2036 (M + H). Anal. calcd. for C25H25N5O3.5H2O (%): C, 
66.40; H, 5.75; N, 15.45; found: C, 66.45; H, 5.70; N, 15.40.  
4.2.2. General procedure for allenylation-anion capture reaction. 
Synthesis of compounds 10 
The method to prepare compounds 10 was the analogous one 
described for the synthesis if compounds 8 but employing K2CO3 
(130 mg, 1.2 mmol) at 80 ºC for 48 h. 
4.2.2.1. 5-Phenyl-1-(2-phenyl-2-propenyl)-1,3-dihydro-2H-
1,4-benzodiazepin-2-one (10a): Yield: 324 mg (92%). Colourless 
prisms; mp 107-109 ºC (petroleum ether/EtOAc). IR (neat): 
3050, 2900, 1673, 1608, 1594, 1447, 1371, 1321 cm-1. δΗ (500 
MHz): 7.14-6.97 (m, 14H, ArH), 5.65 (d, 1H, J 16.3 Hz, 
NCH2αC=CH2), 5.41 (s, 1H, C=CH2α), 5.16 (s, 1H, 
C=CH2β), 4.80 (d, 1H, J 10.5 Hz, NCH2αC=Ο), 4.55 (d, 1H, J 
16.3 Hz, NCH2βC=CH2), 3.80 (d, 1H, J 10.5 Hz, NCH2βC=O). 
δC (126 MHz): 48.7 (18-C), 56.9 (1-C), 115.4 (20-C), 122.2 (5-
C), 123.9 (7-C), 125.6 (12-C, 16-C), 127.8 (13-C, 15-C), 128.2 
(9-C), 128.3 (23-C, 25-C), 129.4 (22-C, 26-C), 129.9 (6-C), 
130.0 (14-C), 130.3 (8-C), 130.7 (24-C), 137.3 (19-C), 138.3 (11-
C), 141.3 (4-C), 142.8 (21-C), 169.5(2-C=O), 170.3 (10-C=N). 
m/z (%) (EI): 423 (M+, 10), 389 (6), 260 (17), 237 (100), 221 
(85), 201 (62), 174 (19), 115 (26). 352 (M, 100), 323 (73), 235 
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(29), 207 (23), 165 (18), 115 (20), 91 (56), 43 (8). Anal. calcd. 
for C24H20N2O·0.25H2O (%): C, 81.80; H, 5.70; N, 7.95; found: 
C, 81.35; H, 5.80; N, 7.90.  
4.2.2.2. 1,3-Dimethyl-5-{1-[2-oxo-5-phenyl-2,3-dihydro-1H-
1,4-benzodiazepin-1-yl)vinyl}-2,4(1H,3H)-pyrimidinedione 
(10b): Yield: 364 mg (88%). Colourless prisms; mp 197-199 ºC 
(petroleum ether/EtOAc). IR (neat): 3050, 1703, 1654, 1448, 
1371 cm-1. δΗ (500 MHz): 7.55 (m, 1H, ArH), 7.45-7.39 (m, 4H, 
ArH), 7.33-7.25 (m, 2H, ArH), 7.20-7.18 (m, 2H, ArH), 6.96 (s, 
1H, C=CHNMe), 5.97 (s, 1H, C=CH2α), 5.50 (d, 1H, J 15.7 Hz, 
NCH2αC=CH2), 5.23 (s, 1H, C=CH2β), 4.77 (d, 1H, J 10.3 Hz, 
NCH2αC=O), 4.35 (d, 1H, J 15.8 Hz, NCH2βC=CH2), 3.80 (d, 
1H, J 10.2 Hz, NCH2βC=O), 3.11 (s, 3H, NMe), 2.95 (s, 3H, 
NMe). δC (126 MHz): 27.9 (CNMe), 36.6 (CNMe), 49.3 (18-C), 
57.0 (1-C), 108.6 (21-C), 119.7 (20-C), 123.1 (5-C), 124.8 (7-C), 
128.2 (12-C, 16-C), 128.8 (13-C, 15-C), 129.9 (9-C), 130.1 (8-
C), 130.9 (14-C), 131.2 (6-C), 134.6 (11-C), 137.51 (19-C), 
140.7 (4-C), 141.0 (28-C), 150.1(25-C), 162.0 (22-C), 169.8 (10-
C), 170.14(2-C).m/z (%) (EI): 414 (M+, 63), 385 (42), 371 (36), 
207 (100), 194 (34), 180 (94), 165 (48), 91 (46), 42 (47). Anal. 
calcd. for C24H22N4O3 (%): C, 69.55; H, 5.30; N, 13.50; found: C, 
69.40; H, 5.40; N, 13.30.  
4.2.2.3. 5-Phenyl-1-[2-(2-thienyl)-2-propenyl]-1,3-dihydro-
2H-1,4-benzodiazepin-2-one (10c): Yield: 322 mg (90%). 
Colourless prisms; mp 59-61 ºC (petroleum ether/EtOAc). IR 
(neat): 3000, 1674, 1607, 1447, 1372 cm-1. δΗ (250 MHz):  7.58-
7.10 (m, 9H, ArH), 6.90-6.86 (m, 2H, ArH), 6.60 (m, 1H, ArH) 
5.50 (d, 1H, J 15.8 Hz, NCH2αC=CH2), 5.43 (s, 1H, C=CH2α), 
5.0 (s, 1H, C=CH2β), 4.85 (d, 1H, J 10.5 Hz, NCH2αC=O), 4.50 
(d, 1H, J 15.8 Hz, NCH2βC=CH2), 3.82 (d, 1H, J 10.5 Hz, 
NCH2βC=O). δC (126 MHz): 48.9 (18-C), 57.0 (1-C), 114.0 (20-
C), 122.3 (5-C), 124.2 (7-C), 124.3 (22-C), 124.5 (23-C), 127.6 
(13-C, 15-C), 128.0 (12-C, 16-C), 129.3 (14-C), 130.1 (8-C), 
130.2 (24-C), 130.2 (6-C), 130.9 (9-C), 136.2 (19-C), 138.4 (11-
C), 141.0 (4-C), 141.3 (21-C), 169.3 (2-C=O), 170.6 (10-C=N). 
m/z (%) (EI): 358 (M+, 41), 329 (14), 297 (34), 235 (52), 165 
(34), 124 (71), 91 (100) and 45 (17). Anal. calcd. for C22H18N2OS 
(%): C, 73.75; H, 5.05; N, 7.80; S, 8.95; found: C, 73.50; H, 
5.10; N, 7.70; S, 8.75. 
4.2.2.4. 1-[3-Methyl-2-(2-thienyl)-2-butenyl]-5-phenyl-1,3-
dihydro-2H-1,4-benzodiazepin-2-one (10d): Yield: 250 mg 
(65%). Pale brown amorphous prisms; mp 49-51 ºC (petroleum 
ether/EtOAc). IR (neat): 3100, 2900, 1674, 1653, 1607, 1447, 
1373 cm-1. δΗ (250 MHz): 7.48-7.18 (m, 9H, ArH), 6.91 (m, 1H, 
ArH), 6.50 (m, 1H, ArH), 6.41 (m, 1H, ArH), 5.43 (d, 1H, J 15.2 
Hz, NCH2αC=C), 4.72 (d, 1H, J 10.7 Hz, NCH2αC=O), 4.55 (d, 
1H, J 15.2 Hz, NCH2βC=C), 3.69 (d, 1H, J 10.6 Hz, 
NCH2βC=O), 1.86, 1.65 (2xs, 6H, 2xCMe). δC (126 MHz): 21.2 
(Me), 23.1 (Me), 48.4 (18-C), 57.0 (1-C), 122.4 (21-C), 123.3 
(20-C), 123.8 (5-C), 124.3 (7-C), 126.3 (25-C), 126.4 (9-C), 
127.9 (13-C,15-C), 129.7 (12-C, 16-C), 129.9 (26-C), 130.0 (14-
C), 130.2 (8-C), 130.4 (6-C), 137.3 (19-C), 138.3 (11-C), 142.1 
(4-C), 142.3 (23-C), 169.8 (C=O), 170.0 (C=N). m/z (%) (EI): 
386 (M+, 100), 371 (15), 357 (10), 325 (13), 304 (8), 249 (12). 
Anal. calcd. for C24H22N2OS· 0.5H2O (%): C, 72.90; H, 5.40; N, 
7.05; found: C, 73.45; H, 4.95; N, 7.00. 
4.2.3. General procedure for the carbonylation anion capture 
reaction. Synthesis of compounds 11, 12 and 14. 
A solution of iodoarene 6 or 13 (1.1 mmol), Pd2(dba)3 (92 mg, 
0.1 mmol),  PPh3 (52 mg, 0.2 mmol) and K2CO3 (166 mg, 1.2 
mmol) and the corresponding benzodiazepine-2-one derivative 5 
or 9 (1 mmol) in dry toluene was prepared in a round-bottomed 
flask. Then, a balloon containing carbon monoxide was adapted 
and the mixture heated to 100-105 ºC for 24-32 h. The reaction 
was cooled to ambient temperature and filtered through filter 
paper. The solvent was evaporated under reduced pressure to 
give a solid which was purified by column chromatography 
(flash silica) obtaining pure compounds 11, 12 and 14. 
4.2.3.1. N-[1-Methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-
benzodiazepin-3-yl) benzamide (11a): Yield: 329 mg (89%). 
Colourless prisms; mp 223-225 ºC (petroleum ether/EtOAc). IR 
(neat): 3108, 2890, 1698, 1688, 1659, 1604, 1445 cm-1. δΗ (250 
MHz): 8.07 (br. d, 1H, J 7.9 Hz, NH), 7.97-7.22 (m, 14H, ArH), 
5.74 (d, 1H, J 7.9 Hz, NCH), 3.50 (s, 3H, NMe). δC (126 MHz): 
35.41(NMe), 67.6 (1-C, NCH), 121.6 (24-C), 124.6 (15-C), 127.3 
(13-C, 17-C), 128.3 (14-C, 16-C), 128.5 (22-C, 26-C), 129.1 (10-
C), 129.8 (23-C, 25-C), 130.7 (6-C), 130.7 (8-C), 131.8 (7-C), 
132.0 (9-C), 134.0 (12-C), 138.1 (5-C), 142.7 (21-C), 167.1 (2-
C=O), 167.7 (20-C=O), 167.9 (11-C=N). m/z (%) (FAB): 370 
(M+ +1, 100), 249 (8), 221 (19), 147 (8), 105 (25), 69 (22), 55 
(28). HRMS (ES): C23H19N3O3Na requires 392.1363; found: 
392.1365. Anal. calcd. for C23H19N3O2·0.5H2O (%): C, 73.00; H, 
5.30; N, 11.10; found: C, 72.90; H, 5.30; N, 10.80. 
4.2.3.2. 1-Methyl-N-(1-methyl-2-oxo-5-phenyl-2,3-dihydro-
1H-1,4-benzodiazepin-3-yl)-1H-indole-6-carboxamide (11b): 
Yield: 342 mg (81%). Pale brown amorphous prisms; mp 136-
138 ºC (petroleum ether/EtOAc). IR (neat): 3113, 2888, 1695, 
1685, 1659, 1600, 1440 cm-1. δΗ (250 MHz): 8.30 (s, 1H, Hc), 
8.14 (d, 1H, J 7.9 Hz, NH), 7.83-7.23 (m, 11H, ArH), 7.10 (d, 
1H, J 3.1 Hz, CHa=CHb), 6.58 (d, 1H, J 3.1 Hz, CHa=CHb), 
5.81 (d, 1H, J 8.0 Hz, CHNH), 3.78 (s, 3H, NMe), 3.49 (s, 3H, 
NMe). δC (126 MHz): 33.0 (NMe), 35.3 (NMe), 67.6 (1-CH), 
102.3, 109.0, 120.9, 121.0, 121.5, 124.5, 125.2, 128.0, 128.2, 
128.3, 129.1, 129.8, 129.9, 130.2, 130.6, 130.7, 131.9, 138.2, 
138.5 (ArC), 142.8 (C=N), 167.4, 168.1 (2xC=O). m/z (%) (EI): 
422 (M+, 15), 264 (24), 237 (37), 223 (19), 158 (100), 130 (33), 
84 (55) and 47 (10). HRMS (ES): C26H22N4O2Na requires 
445.1640; found: 445.1623. Anal. calcd. for C26H22N4O2 
·0.5CH2Cl2 (%): C, 68.45; H, 4.95; N, 12.05; found C, 68.15; H, 
5.05; N, 11.60. 
4.2.3.3. 1-Benzoyl-5-phenyl-1,3-dihydro-2H-1,4-
benzodiazepin-2-one (12a): Yield: 245 mg (72%). Pale yellow 
prisms; mp 73-75 ºC (petroleum ether/EtOAc). IR (neat): 3118, 
2901, 1692, 1682, 1679, 1604, 1455 cm-1. δΗ (250 MHz): 7.80-
7.30 (m, 14H, ArH), 4.86 (d, 1H, J 11.1 Hz, NCH2α), 4.0 (d, 1H, 
J 11.1 Hz, NCH2β). δC (126 MHz): 57.7 (1-CH2), 125.6, 126.34, 
127.41, 128.35, 128.5, 128.6, 128.6, 128.7, 128.8, 129.5, 129.6, 
129.6, 130.3, 130.4, 130.9, 131.4, 133.25, 133.8 (ArC), 170.76 
(C=O), 170.80 (C=O), 171.10 (C=N). m/z (%) (EI): 340 (M+, 6), 
312 (16), 235 (91), 207 (12), 105 (100), 91 (54), 77 (66), 51 (16). 
HRMS (ES): C22H16N2O2Na requires 363.1109; found: 363.1105. 
Anal. calcd. for C22H16N2O2·0.5H2O (%): C, 75.65; H, 4.90; 
found: C, 75.15; H, 4.90. 
4.2.3.4. (7-Chloro-5-phenyl-1-(thiophene-2-carbonyl)-1H-
benzo[e][1,4]diazepin-2(3H)-one (12b): Yield: 338 mg (89%). 
Pale yellow amorphous prisms; mp 79-81 ºC (petroleum 
ether/EtOAc). IR (neat): 3100, 2910, 1698, 1688, 1670, 1624, 
1446, 1342 cm-1. δΗ (500 MHz): 7.71-7.70 (d, 2H, ArH), 7.62 (d, 
1H, J 4.9 Hz, ArH), 7.55-7.35 (m, 7H, ArH), 6.99 (d, 1H, J 4.2 
Hz, ArH), 4.91 (d, 1H, J 10.0 Hz, NCH2α), 3.96 (d, 1H, J 9.10.0 
Hz, NCH2β). δC (126 MHz): 57.4 (1-CH2), 125.5, 128.4, 128.7, 
128.8, 129.5, 129.6, 130.2, 131.1, 131.7, 131.8, 135.9, 136.0, 
137.1, 137.3, 137.8 (ArC), 164.6 (C=O), 169.5 (C=O), 169.5 
(C=N). m/z (%) (ES): 380 (M+, 100). Anal. calcd. for 
C20H13ClN2O2S (%): C, 63.05; H, 3.40; N, 7.35; found: C, 62.95; 
H, 3.40; N, 7.20. 
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4.2.3.5. 2-(1,3-Dimethyl-2-oxo-2,3)-dihydro-1H-indol-3-yl)-N-
[methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-
yl)acetamide (anti-14): Yield: 177 mg (38%). Colourless prisms; 
mp > 230 ºC (petroleum ether/EtOAc). IR (neat): 3050, 2900, 
1713, 1670, 1610, 1494, 1145 cm-1. δΗ (250 MHz):  7.55- 7.25 
(m, 12H, ArH), 7.0 (m, 1H, ArH), 6.82 (d, 1H, J 7.7 Hz, NH), 
5.38 (d, 1H, J 8.3 Hz, 1-C), 3.42 (s, 3H, NMe), 3.24 (s, 3H, 
NMe), 3.10 (d, 1H, J 15.4 Hz, CH2C=O), 2.90 (d, 1H, J 15.5 Hz, 
CH2C=O), 1.43 (s, 3H, NMe). δC (126 MHz): 24.3, 24.4 (26-C, 
NMe), 26.4, 26.5 (4-C, N-Me), 35.4, 35.5 (23-C, Me), 43.4 (21-
C), 45.8 (22-C), 66.9 (1-C), 108.1 (30-C), 121.6 (29-C), 122.4 (6-
C), 122.7 (15-C), 124.4 (9-C), 127.9 (7-C), 128.2 (14-C, 16-C), 
128.9 (27-C), 129.8 (13-C, 17-C), 130.6 (3-C, 28-C), 131.8 (8-
C), 133.3 (32-C), 138.0 (12-C), 142.7 (10-C), 143.3 (5-C), 167.2 
(2-C=O), 167.6 (20-C=O), 168.8 (11-C=N), 180.2 (24-C=O). m/z 
(%) (EI): 466 (M+, 46), 409 (8), 264 (53), 248 (100), 222 (86), 
174 (65), 160 (51), 130 (16), 77 (23). HRMS (ES): 
C28H26N4O3Na requires 489.1903; found: 489.1898. Anal. calcd. 
for C28H26N4O3·H2O (%): C, 69.40; H, 5.75; N, 11.55; found: C, 
69.20; H, 5.60; N, 11.55. 
4.2.3.6. 2-(1,3-Dimethyl-2-oxo-2,3)-dihydro-1H-indol-3-yl)-N-
[methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-
yl)acetamide (syn-14): Yield: 186 mg (40%). Colourless prisms; 
mp > 230 ºC (petroleum ether/EtOAc). IR (neat): 3050, 2905, 
1712, 1670, 1610, 1490, 1145 cm-1. δΗ (250 MHz): 7.71-7.03 (m, 
13H, ArH), 6.85 (d, 1H, J 7.7 Hz, NH), 5.36 (d, 1H, J 8.2 Hz, 
NCH), 3.41 (s, 3H, NMe), 3.23(s, 3H, NMe), 3.08 (d, 1H, J 15.6 
Hz, CH2C=O), 2.96 (d, 1H, J 15.6 Hz, CH2C=O), 1.43 (s, 3H, 
NMe). δC (126 MHz): 24.6, 24.7 (26-C, NMe), 26.4, 26.5 (4-C, 
NMe), 35.3, 35.4 (23-C, Me), 43.3 (21-C), 45.8 (22-C), 66.9 (1-
C), 108.1 (30-C), 121.6 (29-C), 122.3 (6-C), 122.6 (15-C), 124.4 
(9-C), 127.9 (7-C), 128.1 (13-C), 128.6, 128.7 (14-C, 16-C), 
129.7 (27-C), 131.9 (31-C), 132.0 (28-C), 132.2, 132.3 (8-C, 17-
C), 133.4 (32-C), 138.1 (12-C), 142.7 (10-C), 143.4 (5-C), 167.2 
(2-C=O), 167.4 (20-C=O), 169.0 (11-C=N), 180.3 (24-C=O). m/z 
(%) (FAB): 467 (M++1, 100), 221(28), 174(18), 133(25), 
109(12), 57(12). HRMS (ES): C28H26N4O3Na requires 489.1903; 
found: 489.1884. Anal. calcd. for C28H26N4O3·H2O (%): C, 
69.40; H, 5.75; N, 11.55; found: C, 69.60; H, 5.95; N, 11.05. 
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